Recommendations For Future Clinical Trials in R/R MM

Video content above is prompted by the following:

Recommendations for Future Clinical Trials in R/R MM

Medical experts at ASH 2024 emphasized the need for more personalized, adaptive, and innovative approaches in clinical trials for R/R MM. Key recommendations include the following:

Patient-Centered Trial Design – Prioritize trials that account for prior treatment exposure, patient-specific factors, and real-world applicability to improve outcomes across diverse patient populations.

Optimizing Combination Therapies – Investigate novel combinations of immunotherapies, targeted agents, and cellular therapies to enhance efficacy while minimizing toxicity.

Minimal Residual Disease (MRD) as a Surrogate End Point – Incorporate MRD negativity as a key end point in trials to better predict long-term responses and treatment success.

Addressing Unmet Needs in High-Risk Populations – Focus on high-risk cytogenetic subgroups, frail patients, and those with extramedullary disease to develop more effective therapeutic strategies.

Streamlining Regulatory Pathways – Enhance collaboration between researchers, industry, and regulatory agencies to accelerate trial approvals and the availability of promising therapies.

Integration of Biomarker-Driven Approaches – Leverage genomic and molecular profiling to tailor treatment selection and improve response prediction.

These recommendations aim to refine trial methodologies, improve patient outcomes, and accelerate the development of next-generation therapies for R/R MM.